RHYTHM AI has announced the signing of a research collaboration agreement with Biosense Webster. A press release from RHYTHM AI outlines that the agreement grants it access to certain data from the Biosense Webster CARTO 3 System to support a multicentre clinical trial of RHYTHM AI’s STAR Mapping system.
The statement explains that STAR Mapping is a new, AI driven mapping system developed using novel computer algorithms to identify the sources or drivers of atrial fibrillation (AF) from data acquired from the 3D Mapping equipment, Outcomes in a single centre study published in May 2019 demonstrated that 80% of patients treated in a single procedure using STAR Mapping were free of AF without the use of anti-arrhythmia drugs at an average of 18.5 months follow-up. This compares very favourably to a study published in 2015, which demonstrated 48% of patients free form AF at 18 months follow-up using the standard mapping treatment.
Simon Hubbert, chief executive officer of RHYTHM AI says: “We are delighted to have reached agreement with Biosense Webster to collaborate on our forthcoming multi-centre trial. STAR Mapping has demonstrated a significant improvement in outcomes in a single centre study and we look forward to further demonstrating the value of STAR in a UK multicentre trial with recruitment starting later this year.”
